An Australian stem cell and regenerative medicine company

June 11, 2021

MST Access Initiates Research Coverage on Cynata: "Unlocking Stem Cell Therapy Potential"

View Report

View the MST Access Initiation Research Report on Cynata Therapeutics

November 25, 2020

H.C. Wainwright & Co. Company Update: “High-Profile Licensing Deal Underscores Cell Therapy Value; Reiterate Buy”

View Report

View the latest H.C. Wainwright Research Update for Cynata Therapeutics

November 12, 2020

H.C. Wainwright & Co. Company Update: “CYP-004 Phase 3 SCUlpTOR Trial Commences; Reiterate Buy”

View Report

View the latest H.C. Wainwright Research Update for Cynata Therapeutics

November 06, 2020

Pitt Street Research Pty Ltd Company Research Analysis of Cynata Therapeutics: “Stem Cell Pioneer”

View Report

View the latest Pitt Street Research Analysis of Cynata Therapeutics

August 04, 2020

H.C. Wainwright & Co. Company Update: “Positive CYP-001 Two-Year Long-Term Follow-Up Clinical Data; Reiterate Buy”

View Report

View the latest H.C. Wainwright Research Update for Cynata Therapeutics